ID28040A - Reseptor sel t yang dapat larut - Google Patents

Reseptor sel t yang dapat larut

Info

Publication number
ID28040A
ID28040A IDW20002387A ID20002387A ID28040A ID 28040 A ID28040 A ID 28040A ID W20002387 A IDW20002387 A ID W20002387A ID 20002387 A ID20002387 A ID 20002387A ID 28040 A ID28040 A ID 28040A
Authority
ID
Indonesia
Prior art keywords
cell receptor
mhc
cell
dissolve
multivalent
Prior art date
Application number
IDW20002387A
Other languages
English (en)
Inventor
Jakobsen Bent Karsten
Bell John Irving
Gao George Fu
Willcox Benjamin Ernest
Boulter Jonathan Michael
Original Assignee
Avidex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9810759.2A external-priority patent/GB9810759D0/en
Priority claimed from GBGB9821129.5A external-priority patent/GB9821129D0/en
Application filed by Avidex Ltd filed Critical Avidex Ltd
Publication of ID28040A publication Critical patent/ID28040A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IDW20002387A 1998-05-19 1999-05-19 Reseptor sel t yang dapat larut ID28040A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9810759.2A GB9810759D0 (en) 1998-05-19 1998-05-19 Soluble t cell receptor
GBGB9821129.5A GB9821129D0 (en) 1998-09-29 1998-09-29 Multimeric T cell receptor

Publications (1)

Publication Number Publication Date
ID28040A true ID28040A (id) 2001-05-03

Family

ID=26313710

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20002387A ID28040A (id) 1998-05-19 1999-05-19 Reseptor sel t yang dapat larut

Country Status (28)

Country Link
US (4) US20020119149A1 (id)
EP (2) EP1080193A2 (id)
JP (2) JP2002515243A (id)
KR (2) KR20010085250A (id)
CN (2) CN1249229C (id)
AT (1) ATE208819T1 (id)
AU (2) AU746164B2 (id)
BG (1) BG105053A (id)
BR (1) BR9910253A (id)
CA (2) CA2327314A1 (id)
DE (1) DE69900468T2 (id)
DK (1) DK1066380T3 (id)
EA (1) EA200001216A1 (id)
EE (1) EE200000697A (id)
ES (1) ES2168866T3 (id)
HK (1) HK1035739A1 (id)
HR (1) HRP20000790A2 (id)
HU (1) HUP0103614A2 (id)
ID (1) ID28040A (id)
IL (2) IL139344A0 (id)
IS (1) IS5697A (id)
NO (2) NO20005812L (id)
NZ (2) NZ507886A (id)
PL (1) PL364734A1 (id)
PT (1) PT1066380E (id)
SK (1) SK17332000A3 (id)
TR (1) TR200003391T2 (id)
WO (2) WO1999060119A2 (id)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200001216A1 (ru) * 1998-05-19 2001-06-25 Авидекс Лимитед Растворимый т-лимфоцитный рецептор
EP1118661A1 (en) * 2000-01-13 2001-07-25 Het Nederlands Kanker Instituut T cell receptor libraries
JP2004501364A (ja) * 2000-05-25 2004-01-15 スノル・モレキュラー・コーポレーション Ｔ−細胞レセプター相互作用のモジュレーション
JP4317940B2 (ja) 2001-08-31 2009-08-19 イミュノコア・リミテッド 物質
AU2002361559A1 (en) 2001-09-24 2003-04-28 University Of Pittburgh Of The Commonwealth System Of Higher Education Anticancer vaccine and diganostic methods and reagents
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
CA2513044A1 (en) 2002-03-01 2004-08-05 Dyax Corp. Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
ES2523654T3 (es) * 2002-03-01 2014-11-28 Bracco Suisse Sa Constructos multivalentes para aplicaciones terapéuticas y de diagnóstico
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7211240B2 (en) 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
EP2292638A3 (en) 2002-09-27 2011-03-23 Ludwig Institute For Cancer Research MAGE-C2 antigenic peptides and uses thereof
EP1549748B1 (en) * 2002-10-09 2014-10-01 Immunocore Ltd. Single chain recombinant t cell receptors
PT1558643E (pt) * 2002-11-09 2009-08-24 Immunocore Ltd Apresentação de um receptor das células t
GB0227351D0 (en) * 2002-11-22 2002-12-31 Isis Innovation Soluble T-cell receptors
AU2003286263A1 (en) * 2002-12-03 2004-06-23 Avidex Ltd. Complexes of receptors
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances
CA2893995A1 (en) 2003-06-27 2005-01-06 International Institute Of Cancer Immunology, Inc. Method of diagnosis of cancer
JP4773361B2 (ja) * 2003-11-10 2011-09-14 アルター・バイオサイエンス・コーポレーション 可溶性ｔｃｒ分子とその使用方法
US9090673B2 (en) 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
WO2005062959A2 (en) * 2003-12-22 2005-07-14 The University Of Tennessee Research Foundation Isolated t lymphocyte receptors specific for human autoantigens complexed with human mhc molecules and methods of making and using same
GB0411125D0 (en) * 2004-05-19 2004-06-23 Avidex Ltd Method of improving T-cell receptors
WO2007044033A2 (en) * 2004-12-07 2007-04-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
GB0427585D0 (en) * 2004-12-16 2005-01-19 Avidex Ltd Assay
EP1863842A2 (en) 2005-04-01 2007-12-12 MediGene Ltd. High affinity hiv t cell receptors
CA2606287A1 (en) 2005-05-13 2006-11-16 Oxford Biomedica (Uk) Limited Peptide
GB0510627D0 (en) 2005-05-25 2005-06-29 Avidex Ltd Polypeptides
CN101309934B (zh) * 2005-08-31 2014-02-12 悉生物有限公司 修饰的伴侣蛋白10
WO2007085266A1 (en) * 2006-01-30 2007-08-02 Dako Denmark A/S High-speed quantification of antigen specific t-cells in whole blood by flow cytometry
JP2009536922A (ja) * 2006-04-05 2009-10-22 ザ ジェネラル ホスピタル コーポレイション ウイルスに特異的な可溶性ｔ細胞受容体組成物
US8088379B2 (en) 2006-09-26 2012-01-03 The United States Of America As Represented By The Department Of Health And Human Services Modified T cell receptors and related materials and methods
JP5484041B2 (ja) * 2007-02-23 2014-05-07 学校法人関西学院 蛋白質結晶化剤および蛋白質結晶化剤を用いた蛋白質結晶化方法
AU2013206501B2 (en) * 2007-03-05 2016-05-19 International Institute Of Cancer Immunology, Inc. Cancer antigen-specific T-cell receptor gene, peptide encoded by the gene and use of them
CN101668853B (zh) 2007-03-05 2013-07-31 株式会社癌免疫研究所 癌抗原特异性t细胞受体基因、由该基因编码的肽及其使用
EP2155782A2 (en) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
KR100877480B1 (ko) * 2007-06-08 2009-01-07 왕성호 숫자 기억 게임 방법
EP2167537A2 (en) 2007-07-03 2010-03-31 Dako Denmark A/S Compiled methods for analysing and sorting samples
EP2197908A2 (en) 2007-09-27 2010-06-23 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
US10968269B1 (en) 2008-02-28 2021-04-06 Agilent Technologies, Inc. MHC multimers in borrelia diagnostics and disease
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
US8748170B2 (en) 2008-07-25 2014-06-10 University of Pittsburgh—of the Commonwealth System of Higher Education Polypeptides derived from cyclin B1 and uses thereof
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
WO2010151688A2 (en) 2009-06-25 2010-12-29 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors
EP2486049A1 (en) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Human single-chain t cell receptors
GB201002730D0 (en) * 2010-02-18 2010-04-07 Uni I Oslo Product
EP2694709B1 (en) 2011-04-08 2016-09-14 Prognosys Biosciences, Inc. Peptide constructs and assay systems
EP3447140A3 (en) 2011-06-28 2019-05-29 International Institute of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific t cell
EP3333186B9 (en) 2012-03-28 2023-10-04 Gadeta B.V. Combinatorial gamma 9 delta 2 t cell receptor chain exchange
KR102250696B1 (ko) 2012-07-27 2021-05-12 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 Ｔ 세포 수용체 조작
EP3718556A3 (en) 2012-08-31 2020-12-30 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
AU2013312529A1 (en) 2012-09-05 2015-04-16 The University Of Birmingham Target peptides for colorectal cancer therapy and diagnostics
EP3756687A3 (en) 2012-12-13 2021-03-24 University Of Virginia Patent Foundation Target peptides for ovarian cancer therapy and diagnostics
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
EP2972366B1 (en) * 2013-03-15 2020-06-17 Prognosys Biosciences, Inc. Methods for detecting peptide/mhc/tcr binding
DK3071593T3 (da) 2013-11-22 2019-06-11 The Board Of Trustees Of The Univ Of Illionis Modificerede humane t-celle-receptorer med høj affinitet
WO2015091823A1 (en) * 2013-12-19 2015-06-25 Friedrich-Alexander Universität Erlangen-Nürnberg Influenza-specific t-cell receptor and its uses in the detection, prevention and/or treatment of influenza
AU2015228751B2 (en) 2014-03-14 2019-06-20 Adaptimmune Limited TCR libraries
EP3137100B1 (en) 2014-04-15 2023-12-20 University Of Virginia Patent Foundation Isolated t cell receptors and methods of use therefor
GB201409558D0 (en) * 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
CN106279404A (zh) * 2015-05-20 2017-01-04 广州市香雪制药股份有限公司 一种可溶且稳定的异质二聚tcr
MA45352A (fr) 2015-08-07 2018-06-13 Univ Birmingham Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
GB201514875D0 (en) * 2015-08-20 2015-10-07 Autolus Ltd Receptor
JP2018532386A (ja) 2015-09-09 2018-11-08 イミューン デザイン コーポレイション Ｎｙ−ｅｓｏ−１特異的ｔｃｒおよびそれらの使用方法
GB201516277D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR libraries
GB201516272D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516269D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516274D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516265D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516275D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516270D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
CA3010416A1 (en) * 2016-01-06 2017-07-13 Health Research, Inc. Compositions and libraries comprising recombinant t-cell receptors and methods of using recombinant t-cell receptors
EA201891601A1 (ru) 2016-01-10 2019-03-29 Неоткс Терапьютикс Лтд. Способы и композиции, усиливающие эффективность опосредованной суперантигеном иммунотерапии злокачественных опухолей
JP2019510503A (ja) * 2016-04-07 2019-04-18 ブルーバード バイオ， インコーポレイテッド キメラ抗原受容体ｔ細胞組成物
MX2018013445A (es) 2016-05-06 2019-09-09 Juno Therapeutics Inc Celulas diseñadas geneticamente y metodos para obtener las mismas.
RU2766119C2 (ru) 2016-06-02 2022-02-08 Иммунокор Лимитед Режим дозирования для гибридного белка gp100-специфичный перенаправляющий tcr-анти-cd3 scfv
CA3027124A1 (en) * 2016-06-10 2017-12-14 Umc Utrecht Holding B.V. Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
JP6987134B2 (ja) 2016-06-27 2021-12-22 ジュノー セラピューティクス インコーポレイテッド ペプチドエピトープを同定する方法、そのようなエピトープに結合する分子および関連用途
US11072660B2 (en) 2016-10-03 2021-07-27 Juno Therapeutics, Inc. HPV-specific binding molecules
MA50839A (fr) 2016-10-13 2019-08-21 Juno Therapeutics Inc Méthodes et compositions d'immunothérapie impliquant des modulateurs de la voie métabolique du tryptophane
CN110139669A (zh) 2016-11-03 2019-08-16 朱诺治疗学股份有限公司 T细胞疗法和btk抑制剂的组合疗法
WO2018093591A1 (en) 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor
US20190358262A1 (en) 2016-12-03 2019-11-28 Juno Therapeutics, Inc. Methods for modulation of car-t cells
US11590167B2 (en) 2016-12-03 2023-02-28 Juno Therapeutic, Inc. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
ES2961666T3 (es) 2016-12-03 2024-03-13 Juno Therapeutics Inc Métodos para determinar la dosificación de células CAR-T
MA46998A (fr) 2016-12-05 2019-10-09 Juno Therapeutics Inc Production de cellules modifiées pour une thérapie cellulaire adoptive
WO2018132518A1 (en) 2017-01-10 2018-07-19 Juno Therapeutics, Inc. Epigenetic analysis of cell therapy and related methods
EP3571221A2 (en) 2017-01-20 2019-11-27 Juno Therapeutics GmbH Cell surface conjugates and related cell compositions and methods
KR102590672B1 (ko) 2017-01-25 2023-10-18 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
WO2018148180A2 (en) 2017-02-07 2018-08-16 Immune Design Corp. Materials and methods for identifying and treating cancer patients
CA3051481A1 (en) * 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
AU2018222749B2 (en) 2017-02-17 2024-04-18 Fred Hutchinson Cancer Center Combination therapies for treatment of BCMA-related cancers and autoimmune disorders
US20200191774A1 (en) 2017-02-27 2020-06-18 Juno Therapeutics, Inc. Compositions, articles of manufacture and methods related to dosing in cell therapy
CN110582288B (zh) 2017-02-28 2024-09-20 恩多塞特公司 用于car t细胞疗法的组合物和方法
CA3056393A1 (en) 2017-03-14 2018-09-20 Juno Therapeutics, Inc. Methods for cryogenic storage
WO2018187791A1 (en) 2017-04-07 2018-10-11 Juno Therapeutics, Inc Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
WO2018191723A1 (en) 2017-04-14 2018-10-18 Juno Therapeutics, Inc. Methods for assessing cell surface glycosylation
CA3061945A1 (en) 2017-05-01 2018-11-08 Juno Therapeutics, Inc. Combination of a cell therapy and an immunomodulatory compound
CN107216371B (zh) * 2017-05-27 2020-09-18 浙江师范大学 一种成人t细胞白血病的特异性靶向多肽及其应用
CN111201438A (zh) 2017-06-02 2020-05-26 朱诺治疗学股份有限公司 与和细胞疗法相关的毒性有关的制品和方法
CN111225675B (zh) 2017-06-02 2024-05-03 朱诺治疗学股份有限公司 使用过继细胞疗法治疗的制品和方法
WO2019006427A1 (en) 2017-06-29 2019-01-03 Juno Therapeutics, Inc. WALL MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES
EP3661528A1 (en) 2017-07-29 2020-06-10 Juno Therapeutics, Inc. Reagents for expanding cells expressing recombinant receptors
ES2959953T3 (es) 2017-08-09 2024-02-29 Juno Therapeutics Inc Métodos para producir composiciones celulares genéticamente modificadas y composiciones relacionadas
EP3664835B1 (en) 2017-08-09 2024-10-23 Juno Therapeutics, Inc. Methods and compositions for preparing genetically engineered cells
WO2019046832A1 (en) 2017-09-01 2019-03-07 Juno Therapeutics, Inc. GENE EXPRESSION AND EVALUATION OF RISK OF DEVELOPMENT OF TOXICITY FOLLOWING CELL THERAPY
MA50079A (fr) 2017-09-07 2020-07-15 Juno Therapeutics Inc Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire
SG11202002728VA (en) 2017-10-03 2020-04-29 Juno Therapeutics Inc Hpv-specific binding molecules
BR112020008565A2 (pt) 2017-11-01 2020-10-20 Juno Therapeutics Inc processo para a produção de uma composição de célula t
EP3704230B1 (en) 2017-11-01 2024-10-23 Juno Therapeutics, Inc. Process for generating therapeutic compositions of engineered cells
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
WO2019089982A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
WO2019089848A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods associated with tumor burden for assessing response to a cell therapy
CA3081456A1 (en) 2017-11-01 2019-05-09 Editas Medicine, Inc. Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
KR20200099137A (ko) 2017-11-06 2020-08-21 주노 쎄러퓨티크스 인코퍼레이티드 세포 요법 및 감마 세크레타제 억제제의 조합
JP2021502077A (ja) 2017-11-06 2021-01-28 エディタス・メディシン，インコーポレイテッド 免疫療法のためのｔ細胞におけるｃｂｌｂのｃｒｉｓｐｒ−ｃａｓ９編集のための方法、組成物および構成要素
GB201719169D0 (en) 2017-11-20 2018-01-03 Univ College Cardiff Consultants Ltd Novel T-cell receptor and ligand
CN111989106A (zh) 2017-12-01 2020-11-24 朱诺治疗学股份有限公司 基因工程化细胞的给药和调节方法
EP3720480A2 (en) 2017-12-08 2020-10-14 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
BR112020011215A2 (pt) 2017-12-08 2020-11-17 Juno Therapeutics Inc processo para a produção de uma composição de células t modificadas
EA202091407A1 (ru) 2017-12-08 2020-10-20 Джуно Терапьютикс, Инк. Состав бессывороточной среды для культивирования клеток и способы его применения
WO2019144095A1 (en) 2018-01-22 2019-07-25 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for car t cells
JP7181517B2 (ja) * 2018-01-23 2022-12-01 国立大学法人三重大学 Ｔ細胞レセプター
EP3746117A1 (en) 2018-01-31 2020-12-09 Celgene Corporation Combination therapy using adoptive cell therapy and checkpoint inhibitor
PE20201345A1 (es) 2018-04-05 2020-11-25 Juno Therapeutics Inc Receptores de celulas t, y celulas disenadas que expresan los mismos
AU2019247199A1 (en) 2018-04-05 2020-10-15 Editas Medicine, Inc. T cells expressing a recombinant receptor, related polynucleotides and methods
MA52656A (fr) 2018-04-05 2021-02-17 Editas Medicine Inc Procédés de production de cellules exprimant un récepteur recombinant et compositions associées
WO2020018715A1 (en) * 2018-07-17 2020-01-23 Massachusetts Institute Of Technology Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
KR20210059715A (ko) 2018-08-09 2021-05-25 주노 쎄러퓨티크스 인코퍼레이티드 통합된 핵산 평가 방법
JP2021533746A (ja) 2018-08-09 2021-12-09 ジュノー セラピューティクス インコーポレイテッド 操作された細胞およびその組成物を生成するための方法
US20220050114A1 (en) 2018-09-11 2022-02-17 Juno Therapeutics, Inc. Methods for mass spectrometry analysis of engineered cell compositions
WO2020081537A1 (en) * 2018-10-16 2020-04-23 Texas Tech University System Method to express, purify, and biotinylate eukaryotic cell-derived major histocompatibility complexes
CA3117539A1 (en) 2018-10-23 2020-04-30 Regeneron Pharmaceuticals, Inc. Ny-eso-1 t cell receptors and methods of use thereof
EP3874024A1 (en) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Methods for selection and stimulation of cells and apparatus for same
AU2019371462A1 (en) * 2018-11-02 2021-05-20 University Of Washington Orthogonal protein heterodimers
MX2021005021A (es) 2018-11-06 2021-08-11 Juno Therapeutics Inc Proceso para producir celulas t geneticamente modificadas.
CA3117978A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
AU2019387497A1 (en) 2018-11-30 2021-06-24 Juno Therapeutics, Inc. Methods for treatment using adoptive cell therapy
WO2020113188A2 (en) 2018-11-30 2020-06-04 Juno Therapeutics, Inc. Methods for dosing and treatment of b cell malignancies in adoptive cell therapy
KR20220016475A (ko) 2019-05-01 2022-02-09 주노 쎄러퓨티크스 인코퍼레이티드 변형된 ｔｇｆｂｒ2 유전자 좌에서 재조합 수용체를 발현하는 세포, 관련 폴리뉴클레오티드 및 방법
EP3969043A1 (en) 2019-05-15 2022-03-23 Neotx Therapeutics Ltd. Cancer treatment
KR20220031614A (ko) 2019-06-07 2022-03-11 주노 쎄러퓨티크스 인코퍼레이티드 자동화된 t세포 배양
SG11202113356XA (en) 2019-06-12 2021-12-30 Juno Therapeutics Inc Combination therapy of a cell-mediated cytotoxic therapy and an inhibitor of a prosurvival bcl2 family protein
CN114555112A (zh) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
BR112022008023A2 (pt) 2019-10-30 2022-07-12 Juno Therapeutics Gmbh Dispositivos de seleção e/ou estimulação de células e métodos de uso
IL293393A (en) 2019-12-06 2022-07-01 Juno Therapeutics Inc Cell therapy-related toxicity and response-related methods for the treatment of b-cell malignancies
IL294988A (en) 2020-01-24 2022-09-01 Regeneron Pharma Antigen preferentially expressed in melanoma t-cell receptors (prame) and methods of using them
JP2023512209A (ja) 2020-01-28 2023-03-24 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞形質導入のための方法
IL296103A (en) 2020-03-05 2022-11-01 Neotx Therapeutics Ltd Methods and preparations for treating cancer with immune cells
CN115835873A (zh) 2020-05-13 2023-03-21 朱诺治疗学股份有限公司 用于产生表达重组受体的供体分批细胞的方法
WO2021231657A1 (en) 2020-05-13 2021-11-18 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
US20210403528A1 (en) * 2020-05-21 2021-12-30 University College Cardiff Consultants Ltd. Novel T-Cell Receptor and Ligand
WO2021260186A1 (en) 2020-06-26 2021-12-30 Juno Therapeutics Gmbh Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
WO2022060904A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
MX2023004598A (es) 2020-10-23 2023-06-29 Asher Biotherapeutics Inc Fusiones con moléculas de unión al antígeno cd8 para modular la función de las células inmunitarias.
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
US20240108654A1 (en) 2021-03-03 2024-04-04 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
EP4314814A1 (en) 2021-03-22 2024-02-07 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
US20240181052A1 (en) 2021-03-29 2024-06-06 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
JP2024517863A (ja) 2021-05-06 2024-04-23 ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞を刺激し、形質導入する方法
WO2023283446A1 (en) * 2021-07-09 2023-01-12 The Johns Hopkins University Method for surface expression of membrane proteins that have a cytoplasmic c-terminal tail
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy
WO2024006960A1 (en) 2022-06-29 2024-01-04 Juno Therapeutics, Inc. Lipid nanoparticles for delivery of nucleic acids
WO2024054944A1 (en) 2022-09-08 2024-03-14 Juno Therapeutics, Inc. Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
WO2024097642A1 (en) 2022-10-31 2024-05-10 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a combination of adoptive cell therapy and a targeted immunocytokine
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
WO2024124132A1 (en) 2022-12-09 2024-06-13 Juno Therapeutics, Inc. Machine learning methods for predicting cell phenotype using holographic imaging
WO2024161021A1 (en) 2023-02-03 2024-08-08 Juno Therapeutics Gmbh Methods for non-viral manufacturing of engineered immune cells
WO2024211478A1 (en) 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a lymphotoxin beta receptor agonist
WO2024220588A1 (en) 2023-04-18 2024-10-24 Juno Therapeutics, Inc. Cytotoxicity assay for assessing potency of therapeutic cell compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5620689A (en) * 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
US5216132A (en) * 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
US5582996A (en) * 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
DE4040669A1 (de) * 1990-12-19 1992-06-25 Behringwerke Ag Verwendung von peptidpaaren mit extrem hoher spezifischer affinitaet zueinander im bereich der in vitro diagnostik
US5328985A (en) * 1991-07-12 1994-07-12 The Regents Of The University Of California Recombinant streptavidin-protein chimeras useful for conjugation of molecules in the immune system
AR246435A1 (es) * 1992-08-20 1994-08-31 Moreno Saul Jeringa descartable para uso con cubreagujas
WO1996021028A2 (en) * 1995-01-03 1996-07-11 Procept, Inc. Soluble heterodimeric t cell receptors and their antibodies
US5635363A (en) * 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
CA2250166A1 (en) * 1996-03-28 1997-10-02 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US5776746A (en) * 1996-05-01 1998-07-07 Genitope Corporation Gene amplification methods
ATE272070T1 (de) * 1996-08-16 2004-08-15 Harvard College Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
EA200001216A1 (ru) * 1998-05-19 2001-06-25 Авидекс Лимитед Растворимый т-лимфоцитный рецептор

Also Published As

Publication number Publication date
AU3945999A (en) 1999-12-06
WO1999060120A3 (en) 2000-02-03
CN1306572A (zh) 2001-08-01
AU3945699A (en) 1999-12-06
HK1035739A1 (en) 2001-12-07
NO20005811L (no) 2001-01-19
NO20005811D0 (no) 2000-11-17
PT1066380E (pt) 2002-05-31
JP2002515243A (ja) 2002-05-28
AU758949B2 (en) 2003-04-03
EP1066380B1 (en) 2001-11-14
NZ507886A (en) 2003-05-30
US20060155115A1 (en) 2006-07-13
NZ507887A (en) 2002-12-20
CN1249229C (zh) 2006-04-05
WO1999060119A2 (en) 1999-11-25
DE69900468D1 (de) 2001-12-20
ES2168866T3 (es) 2002-06-16
WO1999060119A3 (en) 2000-02-03
EP1080193A2 (en) 2001-03-07
US20020119149A1 (en) 2002-08-29
BG105053A (bg) 2001-09-28
IS5697A (is) 2000-10-31
NO20005812L (no) 2001-01-19
WO1999060120A2 (en) 1999-11-25
KR20010085250A (ko) 2001-09-07
CA2328144A1 (en) 1999-11-25
EA200001216A1 (ru) 2001-06-25
CN1308674A (zh) 2001-08-15
ATE208819T1 (de) 2001-11-15
DK1066380T3 (da) 2002-01-28
NO20005812D0 (no) 2000-11-17
EE200000697A (et) 2002-06-17
AU746164B2 (en) 2002-04-18
HUP0103614A2 (hu) 2002-01-28
TR200003391T2 (tr) 2001-02-21
IL139344A0 (en) 2001-11-25
KR20010043675A (ko) 2001-05-25
US20020142389A1 (en) 2002-10-03
CA2327314A1 (en) 1999-11-25
EP1066380A2 (en) 2001-01-10
PL364734A1 (en) 2004-12-13
HRP20000790A2 (en) 2001-06-30
IL139345A0 (en) 2001-11-25
SK17332000A3 (sk) 2001-06-11
KR100530309B1 (ko) 2005-11-22
US20060093613A1 (en) 2006-05-04
JP2002515244A (ja) 2002-05-28
DE69900468T2 (de) 2002-07-18
BR9910253A (pt) 2002-09-17

Similar Documents

Publication Publication Date Title
ID28040A (id) Reseptor sel t yang dapat larut
HUP0105337A2 (hu) Az immunválaszban szerepet játszó új polipeptidek
DE69939327D1 (de) Funktionelle antagonisten von hedgehog-aktivität
DK1482042T3 (da) Aktive og inaktive CC-kemokinreceptorer og nukleinsyremolekyler der koder for receptoren
SG149693A1 (en) Peptides acting as both glp-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use
TR200101398T2 (tr) Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
DE69434908D1 (de) Rezeptor an der oberfläche von aktivierten t-zellen:act4
TR200102021T2 (tr) TWEAK ve TWEAK reseptörü antagonistleri ve bunların imünolojik bozuklukların iyileştirilmesi için kullanımları
DK1135153T3 (da) Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
NO20031179D0 (no) Chemokin-reseptorbindende heterocykliske forbindelser
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
MA24794A1 (fr) D-methadone, un analgesique nonopioique
SE9702651D0 (sv) Novel compounds
CO5460266A1 (es) Novedosos analogos de la somatostatina
NZ504471A (en) An Ox receptor distinct from known alpha 2-adenoreceptors and imidazoline receptors (I1 and I2) with an affinity for compounds of the oxazoline class
NO882054D0 (no) Sementblanding, saerlig til bruk i borehull.
ATE279515T1 (de) Pct-65 serotonin rezeptor
BR0318631A (pt) os agonistas receptores peptìdeo-1 similares ao glucagon, a preparação e o uso do mesmo
DK0862627T3 (da) Neuropeptid Y-Y5 receptor
DE59809283D1 (de) Inhibitoren für den urokinaserezeptor
ATE279923T1 (de) Urotensin-ii rezeptorantagonisten
SE9702794D0 (sv) New compounds
AU2003302901A8 (en) Human recombinant endooligopeptidase a (heopa)
WO2001023563A3 (en) Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
ZA200204455B (en) Use of dopamine-D3 receptor agonists for the therapy of salt-dependent hypertension.